Michael Martino - Ampio Pharm CEO Director

AMPEDelisted Stock  USD 0.24  0.01  4.35%   

Insider

Michael Martino is CEO Director of Ampio Pharm
Age 67
Phone720 437 6500
Webhttps://ampiopharma.com

Michael Martino Latest Insider Activity

Tracking and analyzing the buying and selling activities of Michael Martino against Ampio Pharm pink sheet is an integral part of due diligence when investing in Ampio Pharm. Michael Martino insider activity provides valuable insight into whether Ampio Pharm is net buyers or sellers over its current business cycle. Note, Ampio Pharm insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ampio Pharm'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Ampio Pharm Management Efficiency

The company has return on total asset (ROA) of (0.6157) % which means that it has lost $0.6157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1396) %, meaning that it created substantial loss on money invested by shareholders. Ampio Pharm's management efficiency ratios could be used to measure how well Ampio Pharm manages its routine affairs as well as how well it operates its assets and liabilities.
Ampio Pharm currently holds 274 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Ampio Pharm has a current ratio of 4.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Ampio Pharm until it has trouble settling it off, either with new capital or with free cash flow. So, Ampio Pharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ampio Pharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ampio to invest in growth at high rates of return. When we think about Ampio Pharm's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Eric EasomAN2 Therapeutics
56
MD FACPSonnet Biotherapeutics Holdings
66
BAO BChSynlogic
46
Qiyong LiuTranscode Therapeutics
60
Manuel DafonsecaSonnet Biotherapeutics Holdings
N/A
MD FACPAN2 Therapeutics
76
John CiniSonnet Biotherapeutics Holdings
71
Gordon JDQuoin Pharmaceuticals Ltd
60
Pablo MDZyVersa Therapeutics
N/A
Owen WallaceMonte Rosa Therapeutics
55
Ajim CFAMonte Rosa Therapeutics
47
Susan DexterSonnet Biotherapeutics Holdings
69
Michael AlleyAN2 Therapeutics
N/A
Silvia BuonamiciMonte Rosa Therapeutics
N/A
Pr MDAC Immune
55
Joseph ZakrzewskiAN2 Therapeutics
62
MBA BSAN2 Therapeutics
49
Carrie CoxCandel Therapeutics
66
Miles NunnAkari Therapeutics PLC
55
MD MSCandel Therapeutics
53
Adam ThomasSynlogic
N/A
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19 and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. Ampio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 18 people. Ampio Pharm [AMPE] is a Pink Sheet which is traded between brokers over the counter. Ampio Pharm is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Ampio Pharm Leadership Team

Elected by the shareholders, the Ampio Pharm's board of directors comprises two types of representatives: Ampio Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ampio. The board's role is to monitor Ampio Pharm's management team and ensure that shareholders' interests are well served. Ampio Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ampio Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Corp CFO
Laura Goldberg, VP Operations
MBBCh MMM, Chief Officer
Daniel CPA, Corporate CFO
Lane Hapke, VP Operations
April Ramirez, Clinical Manager
Michael Martino, CEO Director
David MD, Founder Board

Ampio Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ampio Pharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in Ampio Pink Sheet

If you are still planning to invest in Ampio Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ampio Pharm's history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets